Acute Heart Failure (AHF) Therapeutics Market to Make Huge Impact in near Future: Basic Influencing Factors Driving the Industry 2018-2026

Acute heart failure (AHF) is a progressive condition, in which, the heart muscle is unable to pump enough blood through the heart to meet body’ optimal blood and oxygen level. Congestive heart failure is type of heart failure which requires timely medical attention. Moreover, distinguish between acute and chronic heart failure is important from a clinical standpoint, on which further medication depends. For this, N terminal proB-type natriuretic peptide levels are used for distinguishing acute versus chronic left ventricular dysfunction. An elevated levels of natriuretic peptide were present in patients with acute heart failure compared to those with chronic heart failure patient.

Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1910

Heart failure symptoms vary widely from person to person, depending on types of heart failure patient. The main symptoms of heart failure are caused due to fluid accumulation or congestion and poor blood flow to the body. Symptoms caused by fluid accumulation or congestion includes shortness of breath, weight gain, coughing, swollen ankles, legs or abdomen, while dizziness, rapid heart rate, and fatigue are symptoms associated with reduced blood flow to parts of the body.

Acute Heart Failure (AHF) Therapeutics Market Drivers:

The global acute heart failure therapeutics market is expected to witness significant growth due to approval of new drugs. For instance, in July 2015, Novartis received U.S. Food and Drug Administration (FDA) approval for their Entresto(TM) (sacubitril/valsartan) tablets on the treatment of heart failure with reduced ejection fraction. Entresto is indicated to reduce the risk of cardiovascular death and heart failure hospitalization.

Furthermore, robust pipeline of drugs over the forecast period (2018-2026), is another factor driving growth of acute heart failure therapeutics market. For instance, in March 2017, Cardioxyl Pharmaceuticals’ CXL-1427: a novel nitroxyl (HNO) donor (prodrug), which now operates under the Bristol-Myers Squibb Company (after Cardioxyl Pharmaceuticals’ acquisition by Bristol-Myers Squibb in December 2015); is present in Phase 2 clinical development phase. CXL-1427 is indicated to use as an intravenous treatment for acute decompensated heart failure (ADHF). Successful completion and further launch of Bristol-Myers Squibb’s innovative drug in future, will help to boost the acute heart failure (AHF) therapeutics market growth during the forecast period.

Acute Heart Failure (AHF) Therapeutics Market – Regional Analysis:

Geographically, the market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America is expected to hold dominant position in global acute heart failure (AHF) therapeutics market, due to high prevalence of acute heart failure cases, in this region. For instance, according to Centers for Disease Control and Prevention (CDC), June 2016, around 5.7 million adults in the U.S. suffered from heart failure, in 2016. Moreover, about half of the people who develop heart failure die within 5 years of diagnosis.

Growing prevalence of obesity have increased risk of developing acute heart failure (AHF). According to CDC, May 2017 data findings, between 2013 and 2014, 37.9% of adults aged 20 years and over were obese, in the U.S. Therefore, high prevalence of risk factors and acute heart failure (AHF) cases in these region are expected to drive growth of this market over the forecast period.

Acute Heart Failure (AHF) Therapeutics Market – Competitive Landscape:

Some of the key players in this market are
• Novartis AG,
• Cardiorentis AG,
• Bristol-Myers Squibb Company,
• Amgen Inc.,
• Bayer AG,
• Cytokinetics Inc.,
• Merck & Company Inc.,
• Ono Pharmaceutical Co., Ltd.,
• Pfizer Inc.,

Key players in the marker are engaged in development of new drugs for acute heart failure (AHF). These players are incorporating collaboration strategies to remain competitive in the market.

Request For Customization @ https://www.coherentmarketinsights.com/insight/request-customization/1910

Acute Heart Failure (AHF) Therapeutics Market Taxonomy:

By Disorder Type:

• Right-sided Heart Failure
• Left-sided Heart Failure
◦ Systolic Failure
◦ Diastolic Failure
• Congestive Heart Failure

By Drug Category:

• Angiotensin-Converting Enzyme (ACE) Inhibitors
◦ Captopril (Capoten)
◦ Enalapril (Vasotec)
◦ Fosinopril (Monopril)
◦ Lisinopril (Prinivil, Zestril)
◦ Perindopril (Aceon)
◦ Quinapril (Accupril)
◦ Ramipril (Altace)
◦ Others

• Angiotensin II Receptor Blockers
◦ Candesartan (Atacand)
◦ Losartan (Cozaar)
◦ Valsartan (Diovan)

Aldosterone Antagonists:
• Spironolactone (Aldactone)
• Eplerenone (Inspra)
• Diuretics
• Furosemide (Lasix)
• Bumetanide (Bumex)
• Torsemide (Demadex)
• Chlorothiazide (Diuril)

By Region:
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.